Skip to main navigation Skip to main content

CMH : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Page Path

11
results for

"Jung Hyun Kwon"

Article category

Keywords

Publication year

"Jung Hyun Kwon"

Original Articles

Switching to besifovir in patients with chronic hepatitis B receiving tenofovir disoproxil fumarate: A randomized trial
Hyung Joon Yim, Yeon Seok Seo, Ji Hoon Kim, Won Kim, Young Kul Jung, Jae Young Jang, Sae Hwan Lee, Yun Soo Kim, Chang Wook Kim, Hyoung Su Kim, Jae-Jun Shim, Eun-Young Cho, In Hee Kim, Byung Seok Lee, Jeong-Hoon Lee, Byung Seok Kim, Jeong Won Jang, Hyun Woong Lee, Jung Hyun Kwon, Moon Young Kim, Do Seon Song, Jung Gil Park, Yoon Seok Lee, Eileen L. Yoon, Han Ah Lee, Seong Hee Kang, Jin Mo Yang
Clin Mol Hepatol 2025;31(3):810-822.
Published online January 17, 2025
DOI: https://doi.org/10.3350/cmh.2024.0819
Background/Aims
Besifovir (BSV) showed comparable antiviral activity and superior safety profiles to tenofovir disoproxil fumarate (TDF) in treatment-naïve chronic hepatitis B (CHB). However, no data are available regarding the antiviral efficacy and safety of BSV in patients with CHB who switched from long-term TDF to BSV. This study aimed to evaluate the outcome of a 48-week BSV therapy in patients with CHB who switched from long-term TDF treatment.
Methods
In this non-inferiority trial, 153 CHB patients treated with TDF for ≥48 weeks who had hepatitis B virus (HBV) DNA <20 IU/mL were randomized to receive either BSV 150 mg or TDF 300 mg for 48 weeks.
Results
The per-protocol analysis included 130 patients (BSV group, 64; TDF group, 66). The median duration of TDF use before enrollment was 4.14 years. After 48 weeks, 100.0% and 98.5% patients in the BSV and TDF groups, respectively, met the primary endpoint (HBV DNA <20 IU/mL), demonstrating the non-inferior antiviral efficacy of BSV to TDF (95% confidence interval –0.01 to 0.04; P>0.999), with a predefined margin of –0.18. The mean percentage changes in estimated glomerular filtration rates were slightly better in the BSV group (1.67±11.73%) than in the TDF group (–1.24±11.02%). The BSV group showed a significant improvement in bone turnover biomarkers compared to the TDF group; accordingly, hip and spine bone mineral density increased in the BSV group.
Conclusions
In patients with CHB receiving long-term TDF, switching to BSV may improve renal and bone safety with non-inferior antiviral efficacy compared to that of maintaining TDF.

Citations

Citations to this article as recorded by  Crossref logo
  • Tenofovir amibufenamide in chronic hepatitis B: Lipid changes and 144-week safety with tenofovir disoproxil fumarate-to-tenofovir amibufenamide switch
    Zhi-Hao Zeng, Jin-Qing Liu, Min Zhang, Cai-Liang Qiu, Zhen-Yu Xu
    World Journal of Gastroenterology.2025;[Epub]     CrossRef
  • Correspondence to Editorial on “Switching to Besifovir in Patients with Chronic Hepatitis B Receiving Tenofovir Disoproxil Fumarate: A Randomized Trial”
    Hyung Joon Yim, Seong Hee Kang, Young Kul Jung, Jin Mo Yang
    Clinical and Molecular Hepatology.2025;[Epub]     CrossRef
  • 8,680 View
  • 157 Download
  • Crossref

Viral hepatitis

Male preference for TERT alterations and HBV integration in young-age HBV-related HCC: implications for sex disparity
Jin Seoub Kim, Hye Seon Kim, Kwon Yong Tak, Ji Won Han, Heechul Nam, Pil Soo Sung, Sung Won Lee, Jung Hyun Kwon, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon, Jeong Won Jang
Clin Mol Hepatol 2025;31(2):509-524.
Published online January 2, 2025
DOI: https://doi.org/10.3350/cmh.2024.0545
Background/Aims
Hepatocellular carcinoma (HCC) exhibits significant sex disparities in incidence, yet its molecular mechanisms remain unclear. We explored the role of telomerase reverse transcriptase (TERT) genetic alterations and hepatitis B virus (HBV) integration, both known major contributors to HCC, in sex-specific risk for HBV-related HCC.
Methods
We examined 310 HBV-related HCC tissues to investigate sex-specific TERT promoter (TERT-pro) mutations and HBV integration profiles, stratified by sex and age, and validated with single-cell RNA sequencing (scRNA-seq) data.
Results
Tumors predominantly exhibited TERT-pro mutations (26.0% vs. 0%) and HBV-TERT integration (37.0% vs. 3.0%) compared to non-tumorous tissues. While TERT-pro mutations increased with age in both sexes, younger males (≤60 years) showed marked predominance compared to younger females. Males had significantly more HBV integrations at younger ages, while females initially had fewer integrations that gradually increased with age. Younger males' integrations showed significantly greater enrichment in the TERT locus compared to younger females, alongside a preference for promoters, PreS/S regions, and CpG islands. Overall, TERT genetic alterations were significantly sex-differential in younger individuals (75.3% in males vs. 23.1% in females) but not in older individuals (76.9% vs. 83.3%, respectively). These alterations were associated with increased TERT expression. The skewed TERT abnormalities in younger males were further corroborated by independent scRNA-seq data.
Conclusions
Our findings highlight the critical role of TERT alterations and HBV integration patterns in the male predominance of HCC incidence among younger HBV carriers, offering insights for future exploration to optimize sex-specific patient care and HCC surveillance strategies.

Citations

Citations to this article as recorded by  Crossref logo
  • Transcriptional regulation of tumor suppressor gene RASSF1A by HBx
    Yanhong Kang, Wei Li, Junfeng Wei, Lin Yang, Yi Kang
    Molecular and Cellular Probes.2025; 82: 102034.     CrossRef
  • 6,264 View
  • 155 Download
  • 1 Web of Science
  • Crossref

Snapshot

Viral hepatitis

HBeAg-positive grey-zone patients: Treatment beyond guideline recommendations?
Soon Kyu Lee, Jung Hyun Kwon
Clin Mol Hepatol 2023;29(3):825-827.
Published online May 31, 2023
DOI: https://doi.org/10.3350/cmh.2023.0185

Citations

Citations to this article as recorded by  Crossref logo
  • Liver histological study of patients with chronic hepatitis B virus infection in the grey zone
    Weijia Lin, Rongrong Ding, Shuangshuang Sun, Wei Lu, Yanbin Wang, Xinlan Zhou, Dan Huang, Xiufen Li, Zhanqing Zhang, Liang Chen
    BMC Infectious Diseases.2025;[Epub]     CrossRef
  • Correspondence to editorial on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation”
    Soon Kyu Lee, Jong Young Choi
    Clinical and Molecular Hepatology.2025; 31(2): e161.     CrossRef
  • Distinguishing True Immune Tolerant Hepatitis B Patients: Insights From Long‐Term Clinical Outcomes
    Jung Hyun Kwon, Sung Won Lee, Hee‐Yeon Kim, Do Seon Song, Soon Kyu Lee, Heechul Nam, Soon Woo Nam, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon, Jeong Won Jang
    Journal of Viral Hepatitis.2025;[Epub]     CrossRef
  • Gray zone and the need for expansion in chronic hepatitis B: From theory to clinical practice
    Thang Viet Luong, Ngoc Phan Hong Nguyen, Tri Van Nguyen, Duong Hung Tran, Thien Dinh Nguyen, Hai Nguyen Ngoc Dang
    World Journal of Hepatology.2025;[Epub]     CrossRef
  • Vibration-controlled transient elastography for significant fibrosis in treatment-naïve chronic hepatitis B patients: A systematic review and meta-analysis
    Mi Na Kim, Jihyun An, Eun Hwa Kim, Hee Yeon Kim, Han Ah Lee, Jung Hwan Yu, Young-Joo Jin, Young Eun Chon, Seung Up Kim, Dae Won Jun, Ji Won Han, Miyoung Choi
    Clinical and Molecular Hepatology.2024; 30(Suppl): S106.     CrossRef
  • 8,564 View
  • 112 Download
  • 5 Web of Science
  • Crossref

Letter to the Editor

Autoimmune liver disease represented as primary biliary cholangitis after SARS-CoV-2 infection: A need for population-based cohort study
Soon Kyu Lee, Jung Hyun Kwon, Nara Yoon, Soon Woo Nam, Pil Soo Sung
Clin Mol Hepatol 2022;28(4):926-928.
Published online September 5, 2022
DOI: https://doi.org/10.3350/cmh.2022.0233

Citations

Citations to this article as recorded by  Crossref logo
  • Correspondence on Letter regarding “COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis”
    Ka Shing Cheung, Chiu Hang Mok, Wai Kay Seto, Man Fung Yuen
    Clinical and Molecular Hepatology.2023; 29(1): 176.     CrossRef
  • Post-COVID-19 cholangiopathy: Systematic review
    Mazen Abdalla Rasheed, Vinícius Remus Ballotin, Lucas Goldmann Bigarella, Jonathan Soldera
    World Journal of Methodology.2023; 13(4): 296.     CrossRef
  • Forms of cholangitis to be considered after SARS-CoV-2 infection
    Ju-Yeon Cho, Young-Sun Lee, Soon Sun Kim, Do Seon Song, Jeong-Hoon Lee, Ji Hoon Kim
    Clinical and Molecular Hepatology.2022; 28(4): 929.     CrossRef
  • 4,922 View
  • 82 Download
  • 2 Web of Science
  • Crossref

Original Article

Hepatic neoplasm

Surgery versus radiofrequency ablation in patients with Child- Pugh class-A/single small (≤3 cm) hepatocellular carcinoma
Jungnam Lee, Young-Joo Jin, Seung Kak Shin, Jung Hyun Kwon, Sang Gyune Kim, Young Ju Suh, Yujin Jeong, Jung Hwan Yu, Jin-Woo Lee, Oh Sang Kwon, Soon Woo Nahm, Young Seok Kim
Clin Mol Hepatol 2022;28(2):207-218.
Published online November 24, 2021
DOI: https://doi.org/10.3350/cmh.2021.0294
Background/Aims
We compared the post-treatment overall survival (OS) and recurrence-free survival (RFS) between patients with Child-Turcotte-Pugh (CTP) class-A and single small (≤3 cm) hepatocellular carcinoma (HCC) treated by surgical resection (SR) and radiofrequency ablation (RFA).
Methods
We retrospectively analyzed 391 HCC patients with CTP class-A who underwent SR (n=232) or RFA (n=159) as first-line therapy for single small (≤3 cm) HCC. Survival was compared according to the tumor size (≤2 cm/2–3 cm) and the presence of cirrhosis. Inverse probability of treatment weighting (IPW) method was used to estimate the average causal effect of treatment.
Results
The median follow-up period was 64.8 months (interquartile range, 0.1–162.6). After IPW, the estimated OS was similar in the SR and RFA groups (P=0.215), and even in patients with HCC of ≤2 cm (P=0.816) and without cirrhosis (P=0.195). The estimated RFS was better in the SR group than in the RFA groups (P=0.005), also in patients without cirrhosis (P<0.001), but not in those with HCC of ≤2 cm (P=0.234). The weighted Cox proportional hazards model with IPW provided adjusted hazard ratios (95% confidence interval) for OS, and the RFS after RFA versus SR were 0.698 (0.396–1.232) (P=0.215) and 1.698 (1.777–2.448) (P=0.005), respectively.
Conclusions
SR was similar for OS compared to RFA, but was better for RFS in patients with CTP class-A and single small (≤3 cm) HCC. The RFS was determined by the presence or absence of cirrhosis. Hence, SR rather than RFA should be considered in patients without cirrhosis to prolong the RFS, although there is no OS difference.

Citations

Citations to this article as recorded by  Crossref logo
  • Imaging Classification of Exophytic HCC and Our Experience with Microwave Ablation of Type 2 Lesions
    Soumil Singhal, Pallav Bhatter, Girendra Shankar, Anubhav Khandelwal, Sanjay Saran Baijal
    Indian Journal of Radiology and Imaging.2025; 35(01): 017.     CrossRef
  • Insights on risk score development: Considerations for early-stage hepatocellular carcinoma models
    Zhanna Zhang, Gongqiang Wu
    Clinical and Molecular Hepatology.2025; 31(1): e8.     CrossRef
  • Liver resection versus radiofrequency ablation for solitary small hepatocellular carcinoma measuring ≤3 cm: a systematic review and meta-analysis
    Ming Yang, Guangjun Li, Kunlin Chen, Youwei Wu, Ting Sun, Wentao Wang
    International Journal of Surgery.2025; 111(5): 3456.     CrossRef
  • Recurrence rate, features, and outcome after hepatocellular carcinoma curative resection or ablation according to the IMbrave050 criteria: a real-world study
    Edoardo G. Giannini, Andrea Pasta, Laura Bucci, Maria Corina Plaz Torres, Giulia Pieri, Ciro Celsa, Angelo Sangiovanni, Fabio Piscaglia, Claudia Campani, Gabriele Missale, Gianpaolo Vidili, Giorgia Ghittoni, Filippo Pelizzaro, Francesco Giuseppe Foschi, F
    Digestive and Liver Disease.2025; 57(8): 1673.     CrossRef
  • Microwave ablation versus radiofrequency ablation for hepatocellular carcinoma: a propensity score matching and inverse probability weighting analysis
    Wenlong Yang, Xiaoyan Li, Xufang Tan
    International Journal of Hyperthermia.2025;[Epub]     CrossRef
  • Liver resection versus radiofrequency ablation for hepatocellular carcinoma: A systemic review and meta-analysis
    Zheng He, Guolang Song, Guangchao Yang, Xuan Fu, Meng Tian, Yanhui Zhu
    Frontiers in Oncology.2025;[Epub]     CrossRef
  • Radiofrequency Ablation versus Surgical Resection in Elderly Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
    Jeong-Ju Yoo, Sujin Koo, Gi Hong Choi, Min Woo Lee, Seungeun Ryoo, Jungeun Park, Dong Ah Park
    Current Oncology.2024; 31(1): 324.     CrossRef
  • Thermal ablation versus liver resection for hepatocellular carcinoma in patients with cirrhosis: a systematic review and meta-analysis of propensity-score matched studies
    Qiuxia Wei, Shiyu Xiong, Wanrong Luo, Ming Liang, Baoming Luo
    Clinical and Experimental Medicine.2024;[Epub]     CrossRef
  • Comparison of Surgical Resection and Radiofrequency Ablation in Elderly Patients with Hepatocellular Carcinoma
    Jun Il Kim, Jayoun Lee, Gi Hong Choi, Min Woo Lee, Dong Ah Park, Jeong-Ju Yoo
    Digestive Diseases and Sciences.2024; 69(3): 1055.     CrossRef
  • The Role of Laparoscopic Surgery in the Management of Hepatocellular Carcinoma
    Justin A. Steggerda, Steven A. Wisel, Nicholas N. Nissen, Georgios Voidonikolas, Kambiz Kosari
    Current Hepatology Reports.2024; 23(3): 378.     CrossRef
  • Clinical outcomes of transarterial chemoembolization in Child–Turcotte Pugh class A patients with a single small (≤3 cm) hepatocellular carcinoma
    Jungnam Lee, Young‐Joo Jin, Seung Kak Shin, Jung Hyun Kwon, Sang Gyune Kim, Jung Hwan Yu, Jin‐Woo Lee, Oh Sang Kwon, Soon Woo Nahm, Young Seok Kim
    Journal of Gastroenterology and Hepatology.2024; 39(9): 1924.     CrossRef
  • Nomogram for predicting post-therapy recurrence in BCLC A/B hepatocellular carcinoma with Child-Pugh B cirrhosis
    Wenying Qiao, Shugui Sheng, Yiqi Xiong, Ming Han, Ronghua Jin, Caixia Hu
    Frontiers in Immunology.2024;[Epub]     CrossRef
  • Meta analysis of radiofrequency ablation versus surgical resection in small and large nodule of hepatocellular carcinoma
    Rino A. Gani, Maria Teressa, Refael A. Budiman, Kemal F. Kalista, Cosmas Rinaldi A. Lesmana
    HPB.2024; 26(10): 1216.     CrossRef
  • Primary treatments for solitary hepatocellular carcinoma ≤ 3 cm: A systematic review and network meta-analysis
    Sang-Hoon Kim, Ki-Hun Kim, Byeong-Gon Na, Sung Min Kim, Rak-Kyun Oh
    Annals of Hepato-Biliary-Pancreatic Surgery.2024; 28(4): 397.     CrossRef
  • Microwave Ablation of Recurrent Hepatocellular Carcinoma after Curative Surgical Resection
    Hamzah Adwan, Lars Hammann, Thomas J. Vogl
    Journal of Clinical Medicine.2023; 12(7): 2560.     CrossRef
  • Understanding the causes of recurrent HCC after liver resection and radiofrequency ablation
    Carlo Bosi, Margherita Rimini, andrea Casadei-Gardini, Giorgio Ercolani
    Expert Review of Anticancer Therapy.2023; 23(5): 503.     CrossRef
  • Persistently Elevated HBV Viral-Host Junction DNA in Urine as a Biomarker for Hepatocellular Carcinoma Minimum Residual Disease and Recurrence: A Pilot Study
    Selena Y. Lin, Dina Halegoua-DeMarzio, Peter Block, Yu-Lan Kao, Jesse Civan, Fwu-Shan Shieh, Wei Song, Hie-Won Hann, Ying-Hsiu Su
    Diagnostics.2023; 13(9): 1537.     CrossRef
  • Development and validation of prognostic nomograms for large hepatocellular carcinoma after HAIC
    Wang Yao, Ran Wei, Jia Jia, Wang Li, Mengxuan Zuo, Shuqing Zhuo, Ge Shi, Peihong Wu, Chao An
    Therapeutic Advances in Medical Oncology.2023;[Epub]     CrossRef
  • Construction and validation of a nomogram for HBV-related hepatocellular carcinoma: A large, multicenter study
    Ke Su, Qiuni Shen, Jian Tong, Tao Gu, Ke Xu, Han Li, Hao Chi, Yanlin Liu, Xueting Li, Lianbin Wen, Yanqiong Song, Qulian Guo, Jiali Chen, Zhenying Wu, Yi Jiang, Kun He, Lu Guo, Yunwei Han
    Annals of Hepatology.2023; 28(4): 101109.     CrossRef
  • Tenofovir versus entecavir on the prognosis of hepatitis B virus-related hepatocellular carcinoma: a systematic review and meta-analysis
    Hui Liu, Cheng-Long Han, Bao-Wen Tian, Zi-Niu Ding, Ya-Fei Yang, Yun-Long Ma, Chun-Cheng Yang, Guang-Xiao Meng, Jun-Shuai Xue, Dong-Xu Wang, Zhao-Ru Dong, Zhi-Qiang Chen, Jian-Guo Hong, Tao Li
    Expert Review of Gastroenterology & Hepatology.2023; 17(6): 623.     CrossRef
  • Establishment and application of a survival rate graph model based on biomarkers and imaging indexes after primary hepatocellular carcinoma resection
    Yue Xu, Xiaoqin Yao, Jinmei Li, Guoyuan Zhang, Guangcheng Luo, Qiang Wang
    Cancer Medicine.2023; 12(12): 13329.     CrossRef
  • Comparative Study of Long-Term Outcomes of Laparoscopic Liver Resection versus Radiofrequency Ablation for Single Small Hepatocellular Carcinoma Located in Left Lateral Segments of the Liver
    MeeYoung Kang, Jai Young Cho, Ho-Seong Han, Yoo-Seok Yoon, Hae Won Lee, Boram Lee, Yeshong Park, Jinju Kim, Chang Jin Yoon
    Medicina.2023; 59(6): 1063.     CrossRef
  • Prediction model of hepatitis B virus-related hepatocellular carcinoma in patients receiving antiviral therapy
    Beom Kyung Kim, Sang Hoon Ahn
    Journal of the Formosan Medical Association.2023; 122(12): 1238.     CrossRef
  • Primary non-response to antiviral therapy affects the prognosis of hepatitis B virus-related hepatocellular carcinoma
    Peng Wang, Xinhui Wang, Xiaoli Liu, Fengna Yan, Huiwen Yan, Dongdong Zhou, Lihua Yu, Xianbo Wang, Zhiyun Yang
    BMC Cancer.2023;[Epub]     CrossRef
  • Comparison of Open versus Laparoscopic Approaches in Salvage Hepatectomy for Recurrent Hepatocellular Carcinoma after Radiofrequency Ablation
    Yeshong Park, Jai Young Cho, Ho-Seong Han, Yoo-Seok Yoon, Hae Won Lee, Boram Lee, MeeYoung Kang, Jinju Kim
    Medicina.2023; 59(7): 1243.     CrossRef
  • Tumor size and survival in intrahepatic cholangiocarcinoma treated with surgical resection or ablation
    Elishama N. Kanu, Kristen E. Rhodin, Sabran J. Masoud, Austin M. Eckhoff, Alex J. Bartholomew, Thomas C. Howell, Jiayin Bao, Nicholas T. Befera, Charles Y. Kim, Dan G. Blazer, Sabino Zani, Daniel P. Nussbaum, Peter J. Allen, Michael E. Lidsky
    Journal of Surgical Oncology.2023; 128(8): 1329.     CrossRef
  • Salvage Hepatectomy for Recurrent Hepatocellular Carcinoma after Radiofrequency Ablation: A Retrospective Cohort Study with Propensity Score-Matched Analysis
    Yeshong Park, Ho-Seong Han, Yoo-Seok Yoon, Chang Jin Yoon, Hae Won Lee, Boram Lee, MeeYoung Kang, Jinju Kim, Jai Young Cho
    Cancers.2023; 15(19): 4745.     CrossRef
  • Characteristics and Outcomes of Elderly Hepatocellular Carcinoma Patients following Surgical Resection: Systematic Review and Meta-Analysis
    Elizabeth M. Garcia, Sanjna N. Nerurkar, Eunice X. Tan, Shaun Y.S. Tan, Ern-Wei Peck, Sabrina X.Z. Quek, Readon Teh, Margaret Teng, Andrew Tran, Ee Jin Yeo, Michael Le, Connie Wong, Ramsey Cheung, Daniel Q. Huang
    Digestive Diseases.2023; 43(2): 206.     CrossRef
  • Surgical resection versus ablation for early hepatocellular carcinoma: The debate is still open
    Bo Hyun Kim
    Clinical and Molecular Hepatology.2022; 28(2): 174.     CrossRef
  • Liver resection, radiofrequency ablation, and radiofrequency ablation combined with transcatheter arterial chemoembolization for very-early- and early-stage hepatocellular carcinoma: A systematic review and Bayesian network meta-analysis for comparison of
    Yunlong Zhang, Yunlong Qin, Peng Dong, Houfa Ning, Guangzhi Wang
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Predictors of Hepatocellular Carcinoma Early Recurrence in Patients Treated with Surgical Resection or Ablation Treatment: A Single-Center Experience
    Mauro Giuffrè, Enrico Zuliani, Alessia Visintin, Paola Tarchi, Paola Martingano, Riccardo Pizzolato, Deborah Bonazza, Flora Masutti, Rita Moretti, Lory Saveria Crocè
    Diagnostics.2022; 12(10): 2517.     CrossRef
  • Suboptimal Performance of Hepatocellular Carcinoma Prediction Models in Patients with Hepatitis B Virus-Related Cirrhosis
    Jae Lee, Tae Lim, Hye Lee, Seung Kim, Jun Park, Do Kim, Sang Ahn, Hyun Lee, Jung Lee, Ja Kim, In Min, Beom Kim
    Diagnostics.2022; 13(1): 3.     CrossRef
  • 8,839 View
  • 230 Download
  • 34 Web of Science
  • Crossref

Review

Viral hepatitis

Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop
Hyung Joon Yim, Ji Hoon Kim, Jun Yong Park, Eileen L. Yoon, Hana Park, Jung Hyun Kwon, Dong Hyun Sinn, Sae Hwan Lee, Jeong-Hoon Lee, Hyun Woong Lee
Clin Mol Hepatol 2020;26(4):411-429.
Published online August 28, 2020
DOI: https://doi.org/10.3350/cmh.2020.0049
Clinical practice guidelines are important for guiding the management of specific diseases by medical practitioners, trainees, and nurses. In some cases, the guidelines are utilized as a reference for health policymakers in controlling diseases with a large public impact. With this in mind, practice guidelines for the management of chronic hepatitis B (CHB) have been developed in the United States, Europe, and Asian-Pacific regions to suggest the best-fit recommendations for each social and medical circumstance. Recently, the Korean Association for the Study of the Liver published a revised version of its clinical practice guidelines for the management of CHB. The guidelines included updated information based on newly available antiviral agents, the most recent opinion on the initiation and cessation of treatment, and updates for the management of drug resistance, partial virological response, and side effects. Additionally, CHB management in specific situations was comprehensively revised. This review compares the similarities and differences among the various practice guidelines to identify unmet needs and improve future recommendations.

Citations

Citations to this article as recorded by  Crossref logo
  • Effects of tenofovir disoproxil fumarate on intrahepatic viral burden and liver immune microenvironment in patients with chronic hepatitis B
    David Z Pan, Cameron M Soulette, Abhishek Aggarwal, Dong Han, Nicholas van Buuren, Peiwen Wu, Becket Feierbach, Jaw-Town Lin, Cheng-Hao Tseng, Chi-Yi Chen, Bryan Downie, Hongmei Mo, Lauri Diehl, Li Li, Simon P Fletcher, Scott Balsitis, Ricardo Ramirez, Vi
    Gut.2025; 74(4): 628.     CrossRef
  • Limited Value of HBV‐RNA for Relapse Prediction After Nucleos(t)ide Analogue Withdrawal in HBeAg‐negative Hepatitis B Patients
    Valerie Ohlendorf, Maximilian Wübbolding, Christoph Höner zu Siederdissen, Birgit Bremer, Katja Deterding, Heiner Wedemeyer, Markus Cornberg, Benjamin Maasoumy
    Journal of Viral Hepatitis.2025;[Epub]     CrossRef
  • Overview of chronic hepatitis B management
    Angela Jun, Sherona Bau, John S. Kim, Susanne J. Phillips
    The Nurse Practitioner.2025; 50(1): 7.     CrossRef
  • Effectiveness and safety of tenofovir amibufenamide and tenofovir alafenamide in treating elderly patients diagnosed with decompensated hepatitis B cirrhosis: a retrospective cohort study
    Xinye Qiu, Yue Yin, Shibin Zhang, Wei Liu
    Frontiers in Pharmacology.2025;[Epub]     CrossRef
  • Decreased incidence of hepatocellular carcinoma in non‐cirrhotic and low‐viral‐load chronic hepatitis B patients treated with nucleotide/nucleoside analogs
    Tyng‐Yuan Jang, Chia‐Yen Dai
    Advances in Digestive Medicine.2025;[Epub]     CrossRef
  • Global burden of HBV-related liver disease: Primary liver cancer due to chronic HBV infection increased in over one-third of countries globally from 2000 to 2021
    Pojsakorn Danpanichkul, Kwanjit Duangsonk, Vincent L. Chen, Preenapun Saokhieo, Disatorn Dejvajara, Banthoon Sukphutanan, Majd B. Aboona, Chawin Lopimpisuth, Yanfang Pang, Andrew F. Ibrahim, Michael B. Fallon, Daniel Q. Huang, Donghee Kim, Amit G. Singal,
    Hepatology.2025; 82(5): 1274.     CrossRef
  • Tenofovir alafenamide-related hyperlipidemia and cardiovascular risk
    Ankur Jindal, Manoj Kumar
    Hepatology International.2025; 19(4): 701.     CrossRef
  • Comparison of bone mineral density changes between denosumab and bisphosphonates in tenofovir-exposed chronic hepatitis B patients with osteoporosis
    Yunmi Ko, Byeong Geun Song, Hyunjae Shin, Youngsu Park, Jeayeon Park, Min Kyung Park, Yun Bin Lee, Su Jong Yu, Dong Hyun Sinn, Yoon Jun Kim, Jung-Hwan Yoon, Seung Shin Park, Moon Haeng Hur, Jeong-Hoon Lee
    Osteoporosis International.2025; 36(8): 1391.     CrossRef
  • Besifovir dipivoxil maleate versus other antivirals in reducing hepatocellular carcinoma in chronic hepatitis B
    Jae Seung Lee, Sung Won Lee, Hae Lim Lee, Jeong-Ju Yoo, Yeon Seok Seo, Su Jong Yu, Hyung Joon Yim, Young Kul Jung, Jisu Moon, Hye Won Lee, Mi Na Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Sang Gyune Kim, Seung Up Kim
    Scientific Reports.2025;[Epub]     CrossRef
  • Time for a globally unified chronic HBV terminology?
    Su Wang, Catherine Freeland, Seng Gee Lim, Hailemichael Desalegn, Chari Cohen, Harry L.A. Janssen
    JHEP Reports.2025; 7(12): 101570.     CrossRef
  • Chronic hepatitis B: Is it time for expanded antiviral treatment?
    Manish Manrai, Atul A Jha, Aditya V Pachisia, Saurabh Dawra
    World Journal of Virology.2025;[Epub]     CrossRef
  • Modeling the Impact of Treatment on Hepatitis B Burden: Mathematical Analysis and Simulation
    Jean Pierre II Kouenkam, Joseph Mbang, Gilbert Chendjou, Herieth Rwezaura, Jean Tchuenche
    Operations Research Forum.2025;[Epub]     CrossRef
  • Precision Management of Patients with HBV Infection
    Chih-Lin Lin, Jia-Horng Kao
    Current Hepatology Reports.2024; 23(1): 22.     CrossRef
  • Management of Hepatitis B in Pregnancy
    Jeanette Rios, Lital Aliasi-Sinai, Natalia Schmidt, Tatyana Kushner
    Current Hepatology Reports.2024; 23(2): 278.     CrossRef
  • Noninferiority Outcomes of Besifovir Compared to Tenofovir Alafenamide in Treatment-Naïve Patients with Chronic Hepatitis B
    Tae Hyung Kim, Ji Hoon Kim, Hyung Joon Yim, Yeon Seok Seo, Sun Young Yim, Young-Sun Lee, Young Kul Jung, Jong Eun Yeon, Soon Ho Um, Kwan Soo Byun
    Gut and Liver.2024; 18(2): 305.     CrossRef
  • Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patient with chronic hepatitis B
    Heechul Nam, Ji Won Han, Soon Kyu Lee, Hyun Yang, Hae Lim Lee, Pil Soo Sung, Myeong Jun Song, Jung Hyun Kwon, Jeong Won Jang, U‐Im Chang, Chang Wook Kim, Soon Woo Nam, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon, Jin Mo Yang, Hee Yeon Kim
    Journal of Gastroenterology and Hepatology.2024; 39(8): 1673.     CrossRef
  • Hepatitis B surface antigen loss in chronic hepatitis B patients with low‐viral‐load
    Tyng‐Yuan Jang, Batbold Batsaikhan, Yo‐Chia Chen, Chia‐Yen Dai
    Journal of Gastroenterology and Hepatology.2024; 39(11): 2327.     CrossRef
  • Modern etiotropic therapy of chronic viral hepatitis B
    E. B. Bun'kova, N. A. Bileva, A. E. Bilev, M. I. Sinel'nikov
    Bulletin of the Medical Institute "REAVIZ" (REHABILITATION, DOCTOR AND HEALTH).2024; 14(4): 76.     CrossRef
  • Low level of hepatitis B viremia is associated with increased risk of hepatocellular carcinoma in compensated cirrhotic patients
    Wei-Chun Lin, Ke Lin, Ming-Kai Li, Xiao Liu, Yi-Fei Huang, Xing Wang, Bin Wu
    World Journal of Hepatology.2024; 16(11): 1321.     CrossRef
  • Safety and efficacy of 48-week pegylated interferon-α-2b therapy in patients with hepatitis B virus-related compensated liver cirrhosis: a pilot observational study
    Zehong Wang, Xuanxuan Wang, Li Zhou, Shaoyuan Shi, Yongli Hua, Yinong Feng
    Frontiers in Medicine.2024;[Epub]     CrossRef
  • Limited stability of Hepatitis B virus RNA in plasma and serum
    Valerie Ohlendorf, Birgit Bremer, Lisa Sandmann, Carola Mix, Tammo Tergast, Markus Cornberg, Heiner Wedemeyer, Katja Deterding, Benjamin Maasoumy
    Scientific Reports.2024;[Epub]     CrossRef
  • Comparison of lipid profile alterations in chronic hepatitis b patients receiving tenofovir alafenamide or tenofovir disoproxil fumarate
    Shenglong Lin, Wanlong Huang, Ziyuan Liao, Huaxi Ma, Wenjun Wu, Minghua Lin, Defu Huang, Haibing Gao
    Scientific Reports.2024;[Epub]     CrossRef
  • Post-operative recurrence of liver cancer according to antiviral therapy for detectable hepatitis B viremia: A nationwide study
    Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin-Ha Yoon, Beom Kyung Kim
    European Journal of Internal Medicine.2023; 107: 66.     CrossRef
  • Comparable Mortality Between Asian Patients with Chronic Hepatitis B Under Long-Term Antiviral Therapy vs Matched Control: A Population-Based Study
    Byungyoon Yun, Juyeon Oh, Sang Hoon Ahn, Jin-Ha Yoon, Beom Kyung Kim
    American Journal of Gastroenterology.2023; 118(6): 1001.     CrossRef
  • Correspondence on Editorial regarding “Impact of nationwide hepatocellular carcinoma surveillance on the prognosis in patients with chronic liver disease”
    Won Sohn, Yong-Han Paik
    Clinical and Molecular Hepatology.2023; 29(1): 182.     CrossRef
  • Diagnostic Efficacy of Serum Asialo α1-Acid Glycoprotein Levels for Advanced Liver Fibrosis and Cirrhosis in Patients with Chronic Hepatitis B Compared to That in Healthy Subjects: A Prospective Study
    Yoonseok Lee, Seryun Bae, Ji Hoon Kim, Minjung Kwak, So Yeon Jeon, Taehyung Kim, Sun Young Yim, Young-Sun Lee, Young Kul Jung, Yeon Seok Seo, Hyung Joon Yim, Jong Eun Yeon, Kwan Soo Byun
    Journal of Clinical Medicine.2023; 12(2): 712.     CrossRef
  • Comparable outcomes between immune-tolerant and active phases in noncirrhotic chronic hepatitis B: a meta-analysis
    Han Ah Lee, Seung Up Kim, Yeon Seok Seo, Sang Hoon Ahn, Chai Hong Rim
    Hepatology Communications.2023; 7(2): e0011.     CrossRef
  • miR-548c-3p targets TRIM22 to attenuate the Peg–IFN–α therapeutic efficacy in HBeAg-positive patients with chronic hepatitis B
    Ni Lin, Long Wang, Zhaopei Guo, Shaoying Guo, Can Liu, Jinpiao Lin, Songhang Wu, Siyi Xu, Hongyan Guo, Fenglin Fang, Ya Fu, Qishui Ou
    Antiviral Research.2023; 213: 105584.     CrossRef
  • Pre-S1 Mutations as Indicated by Serum Pre-S1 Antigen Negative is Associated with an Increased Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients
    Xingxin Zhang, Chenjian Gu, Qian Wei, Yirong Cao, Weimin She, Hong Shi, Youhua Xie, Jinsheng Guo
    Journal of Hepatocellular Carcinoma.2023; Volume 10: 599.     CrossRef
  • Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase
    Jeong-Ju Yoo, Soo Young Park, Ji Eun Moon, Yu Rim Lee, Han Ah Lee, Jieun Lee, Young Seok Kim, Yeon Seok Seo, Sang Gyune Kim
    Clinical and Molecular Hepatology.2023; 29(2): 482.     CrossRef
  • Outcome of untreated low-level viremia versus antiviral therapy-induced or spontaneous undetectable HBV-DNA in compensated cirrhosis
    Daniel Q. Huang, Nobuharu Tamaki, Hyung Woong Lee, Soo Young Park, Yu Rim Lee, Hye Won Lee, Seng Gee Lim, Tae Seop Lim, Masayuki Kurosaki, Hiroyuki Marusawa, Toshie Mashiba, Masahiko Kondo, Yasushi Uchida, Haruhiko Kobashi, Koichiro Furuta, Namiki Izumi,
    Hepatology.2023; 77(5): 1746.     CrossRef
  • Comparison of decline in renal function between patients with chronic hepatitis B with or without antiviral therapy
    Jae Seung Lee, Chan‐Young Jung, Jung Il Lee, Sang Hoon Ahn, Beom Seok Kim, Seung Up Kim
    Alimentary Pharmacology & Therapeutics.2023; 58(1): 99.     CrossRef
  • The urgency to expand the antiviral indications of general chronic hepatitis B patients
    Ping Fan, Lan-Qing Li, En-Qiang Chen
    Frontiers in Medicine.2023;[Epub]     CrossRef
  • Effectiveness and safety of tenofovir amibufenamide and its comparison with tenofovir alafenamide in patients with chronic hepatitis B: results from a retrospective real-world study
    Lanqing Li, Jing Zhou, Yujing Li, Fada Wang, Dongmei Zhang, Menglan Wang, Yachao Tao, Enqiang Chen
    Frontiers in Pharmacology.2023;[Epub]     CrossRef
  • Efficacy of Antiviral Prophylaxis up to 6 or 12 Months From Completion of Rituximab in Resolved Hepatitis B Patients: A Multicenter, Randomized Study
    Heejoon Jang, Su Jong Yu, Hong Ghi Lee, Tae Min Kim, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, Jung-Hwan Yoon, Yoon Jun Kim
    Journal of Korean Medical Science.2023;[Epub]     CrossRef
  • Changes in liver stiffness values assessed using transient elastography in chronic hepatitis B patients treated with tenofovir disoproxil fumarate: a prospective observational study
    Heejin Cho, Yun Bin Lee, Yeonjung Ha, Young Eun Chon, Mi Na Kim, Joo Ho Lee, Hana Park, Kyu Sung Rim, Seong Gyu Hwang
    BMC Gastroenterology.2023;[Epub]     CrossRef
  • Prediction model of hepatitis B virus-related hepatocellular carcinoma in patients receiving antiviral therapy
    Beom Kyung Kim, Sang Hoon Ahn
    Journal of the Formosan Medical Association.2023; 122(12): 1238.     CrossRef
  • Treated chronic hepatitis B is a good prognostic factor of diffuse large B-cell lymphoma
    Jeayeon Park, Sung Won Chung, Yun Bin Lee, Hyunjae Shin, Moon Haeng Hur, Heejin Cho, Min Kyung Park, Jeonghwan Youk, Ji Yun Lee, Jeong-Ok Lee, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Tae Min Kim, Jeong-Hoon Lee
    Clinical and Molecular Hepatology.2023; 29(3): 794.     CrossRef
  • Hepatocellular Carcinoma and Hepatitis: Advanced Diagnosis and Management with a Focus on the Prevention of Hepatitis B-Related Hepatocellular Carcinoma
    Soo Ryang Kim, Soo Ki Kim
    Diagnostics.2023; 13(20): 3212.     CrossRef
  • The Connection between MiR-122 and Lymphocytes in Patients Receiving Treatment for Chronic Hepatitis B Virus Infection
    Marina Manea, Dimitri Apostol, Ileana Constantinescu
    Microorganisms.2023; 11(11): 2731.     CrossRef
  • Patient Preferences and Their Influence on Chronic Hepatitis B-A Review
    Lin Zhang, Yunyue Liu, Jinping Tian
    Patient Preference and Adherence.2023; Volume 17: 3119.     CrossRef
  • Antiviral therapy reduces hepatocellular carcinoma through suppressing hepatitis B virus replication may improve ER stress, mitochondrial and metabolic dysfunctions and decrease p62 in hybridized mice with single HBV transgene and miR‐122
    Yuh‐Jin Liang, Yu‐Wei Chiou, Abby Pei‐Ting Chiu, Ming‐Shi Shiao, Wei Teng, Chin‐Wei Lin, Mei‐Ling Cheng, Yen‐Hua Huang, Kung‐Hao Liang, Chien‐Wei Su, Chi‐Yu Lai, Chih‐Li Chen, Jaw‐Ching Wu
    Journal of Medical Virology.2023;[Epub]     CrossRef
  • Air pollution impede ALT normalization in chronic hepatitis B patients treated with nucleotide/nucleoside analogues
    Tyng-Yuan Jang, Chi-Chang Ho, Chih-Da Wu, Chia-Yen Dai, Pau-Chung Chen
    Medicine.2023; 102(43): e34276.     CrossRef
  • Effectiveness and Safety of Tenofovir Alafenamide in Treatment-Naïve and Treatment-Experienced Patients with Chronic Hepatitis B: Results of a Real-World Study from China
    Lan-Qing Li, Fa-Da Wang, Jing Zhou, Meng-Lan Wang, Yachao Tao, En-Qiang Chen
    Hepatitis Monthly.2023;[Epub]     CrossRef
  • Influence of Renal Function on the Single‐Dose Pharmacokinetics of Besifovir, a Novel Antiviral Agent for theTreatment of Hepatitis B Virus Infection
    Jun Gi Hwang, Yu Kyong Kim, Young‐sim Choi, Soon Kil Kwon, Joung‐Ho Han, Min Kyu Park
    The Journal of Clinical Pharmacology.2022; 62(1): 46.     CrossRef
  • Average corticosteroid dose and risk for HBV reactivation and hepatitis flare in patients with resolved hepatitis B infection
    Zhenyu Zhong, Weiting Liao, Lingyu Dai, Xiaojie Feng, Guannan Su, Yu Gao, Qiuying Wu, Peizeng Yang
    Annals of the Rheumatic Diseases.2022; 81(4): 584.     CrossRef
  • Episodic Detectable Viremia Does Not Affect Prognosis in Untreated Compensated Cirrhosis With Serum Hepatitis B Virus DNA <2,000 IU/mL
    Hye Won Lee, Soo Young Park, Yu Rim Lee, Hyein Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    American Journal of Gastroenterology.2022; 117(2): 288.     CrossRef
  • Correlation of hepatitis B surface antigen expression with clinicopathological and biochemical parameters in liver biopsies: A comprehensive study
    Anil Alpsoy, Haydar Adanir, Zeynep Bayramoglu, Gulsum Ozlem Elpek
    World Journal of Hepatology.2022; 14(1): 260.     CrossRef
  • External Validation of the FSAC Model Using On-Therapy Changes in Noninvasive Fibrosis Markers in Patients with Chronic Hepatitis B: A Multicenter Study
    Jae Seung Lee, Hyun Woong Lee, Tae Seop Lim, In Kyung Min, Hye Won Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Cancers.2022; 14(3): 711.     CrossRef
  • Translational Strategies to Eliminate Chronic Hepatitis B in Children: Prophylaxis and Management in East Asian Countries
    Ben Kang, Dae Yong Yi, Byung-Ho Choe
    Frontiers in Pediatrics.2022;[Epub]     CrossRef
  • Validation of PH and Varices Risk Scores for Prediction of High-Risk Esophageal Varix and Bleeding in Patients with B-Viral Cirrhosis
    Seunghwan Shin, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Diagnostics.2022; 12(2): 441.     CrossRef
  • Long‐term renal safety between patients with chronic hepatitis B receiving tenofovir vs. entecavir therapy: A multicenter study
    Young Eun Chon, Soo Young Park, Seung Up Kim, Han Pyo Hong, Jae Seung Lee, Hye Won Lee, Mi Na Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Journal of Viral Hepatitis.2022; 29(4): 289.     CrossRef
  • A Multi-Center, Double-Blind Randomized Controlled Phase III Clinical Trial to Evaluate the Antiviral Activity and Safety of DA-2802 (Tenofovir Disoproxil Orotate) and Viread (Tenofovir Disoproxil Fumarate) in Chronic Hepatitis B Patients
    Hyung Joon Kim, Ju Hyun Kim, Jong Eun Yeon, Yeon Seok Seo, Jeong Won Jang, Yong Kyun Cho, Byoung Kuk Jang, Byung Hoon Han, Changhyeong Lee, Joon Hyeok Lee, Jung-Hwan Yoon, Kang Mo Kim, Moon Young Kim, Do Young Kim, Neung Hwa Park, Eun Young Cho, June Sung
    Journal of Korean Medical Science.2022;[Epub]     CrossRef
  • Hepatitis B Core-Related Antigen Is Useful for Predicting Phase and Prognosis of Hepatitis B e Antigen-Positive Patients
    Han Ah Lee, Hyun Woong Lee, Younhee Park, Hyon-Suk Kim, Yeon Seok Seo
    Journal of Clinical Medicine.2022; 11(6): 1729.     CrossRef
  • Cost-effectiveness of antiviral therapy in untreated compensated cirrhosis patient with serum HBV–DNA level < 2000 IU/mL
    Hankil Lee, Sungin Jang, Sang Hoon Ahn, Beom Kyung Kim
    Hepatology International.2022; 16(2): 294.     CrossRef
  • KASL clinical practice guidelines for management of chronic hepatitis B

    Clinical and Molecular Hepatology.2022; 28(2): 276.     CrossRef
  • Clinical Indication of Aspirin Associated With Reduced Risk of Liver Cancer in Chronic Hepatitis B: A Nationwide Cohort Study
    Byungyoon Yun, Sang Hoon Ahn, Jin-Ha Yoon, Beom Kyung Kim
    American Journal of Gastroenterology.2022; 117(5): 758.     CrossRef
  • Fibrotic burden during antiviral therapy for chronic hepatitis B, not ALT level, independently predicts liver cancer risk
    David Sooik Kim, Beom Kyung Kim, Yeon Seok Seo, Byung Seok Kim, Byoung Kuk Jang, Sang Gyune Kim, Ki Tae Suk, Jin‐Woo Lee, Soung Won Jeong, Seung Up Kim
    Liver International.2022; 42(8): 1902.     CrossRef
  • Extrahepatic carcinogenicity of oral nucleos(t)ide analogues in chronic hepatitis B carriers: A 35,000‐Korean outcome study
    Jihye Lim, Jung‐Bok Lee, Jihyun An, Gi‐Won Song, Kang Mo Kim, Han Chu Lee, Ju Hyun Shim
    Journal of Viral Hepatitis.2022; 29(9): 756.     CrossRef
  • Statin use and risk of progression to liver cirrhosis in chronic hepatitis B independent of conventional risk factors: A nationwide study
    Byungyoon Yun, Sang Hoon Ahn, Jin‐Ha Yoon, Beom Kyung Kim
    Hepatology Communications.2022; 6(9): 2455.     CrossRef
  • Association of tenofovir and entecavir use with prognosis after surgical resection for hepatitis B virus-related hepatocellular carcinoma
    Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin-Ha Yoon, Beom Kyung Kim
    European Journal of Internal Medicine.2022; 103: 122.     CrossRef
  • [Retracted] Finite versus Indefinite Nucleos(t)ide Analogue Therapy of Patients with Chronic Hepatitis B Exhibiting Negative HBsAg Levels after Treatment
    Haixia Sun, Yinhui Liu, Yufeng Zhang, Yusheng Jie, Yuankai Wu, Zhanyi Li, Xuxia Wei, Xiangyong Li, Bing Niu
    BioMed Research International.2022;[Epub]     CrossRef
  • Validation of Hepatocellular Carcinoma Risk Prediction Models in Patients with Hepatitis B-Related Cirrhosis
    Ran Cheng, Xiaoyuan Xu
    Journal of Hepatocellular Carcinoma.2022; Volume 9: 987.     CrossRef
  • Response to Liao et al.
    Byungyoon Yun, Jin-Ha Yoon, Beom Kyung Kim
    American Journal of Gastroenterology.2022; 117(10): 1718.     CrossRef
  • Non-Inferior Efficacy of Tenofovir Disoproxil to Tenofovir Disoproxil Fumarate in Virologically Suppressed Chronic Hepatitis B Patients
    Hyung Joon Yim, Ji Hoon Kim, Yong Kyun Cho, Young Oh Kweon, Hyun Chin Cho, Jae Seok Hwang, Changhyeong Lee, Moon Soo Koh, Yang-Hyun Baek, Young-Min Park, Jeong-Hoon Lee, Seung Up Kim, Min-Kyu Kang, Neung Hwa Park, June Sung Lee, Young Eun Chon, Gab Jin Ch
    Drug Design, Development and Therapy.2022; Volume 16: 3263.     CrossRef
  • Prognostic Impact of MAFLD Following Surgical Resection of Hepatitis B Virus-Related Hepatocellular Carcinoma: A Nationwide Cohort Study
    Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin-Ha Yoon, Beom Kyung Kim
    Cancers.2022; 14(20): 5002.     CrossRef
  • Long-Term Prediction Model for Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Receiving Antiviral Therapy: Based on Data from Korean Patients
    Ji Hun Lee, Seung Kak Shin, Seong Hee Kang, Tae Hyung Kim, Hyung Joon Yim, Sun Young Yim, Young-Sun Lee, Young Kul Jung, Ji Hoon Kim, Yeon Seok Seo, Jong Eun Yeon, Oh Sang Kwon, Soon Ho Um, Kwan Soo Byun
    Journal of Clinical Medicine.2022; 11(22): 6613.     CrossRef
  • Impacts of muscle mass dynamics on prognosis of outpatients with cirrhosis
    Tae Hyung Kim, Young Kul Jung, Hyung Joon Yim, Joo Won Baik, Sun Young Yim, Young-Sun Lee, Yeon Seok Seo, Ji Hoon Kim, Jong Eun Yeon, Kwan Soo Byun
    Clinical and Molecular Hepatology.2022; 28(4): 876.     CrossRef
  • Secondary prevention of hepatitis B virus‐related hepatocellular carcinoma with current antiviral therapies
    Jonggi Choi, Young‐Suk Lim
    The Kaohsiung Journal of Medical Sciences.2021; 37(4): 262.     CrossRef
  • External validation of CAGE‐B and SAGE‐B scores for Asian chronic hepatitis B patients with well‐controlled viremia by antivirals
    Jung Hyun Ji, Soo Young Park, Won Jeong Son, Hye Jung Shin, Hyein Lee, Hye Won Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Journal of Viral Hepatitis.2021; 28(6): 951.     CrossRef
  • Association of Physical Activity with the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B
    Ho Soo Chun, Sojeong Park, Minjong Lee, Yuri Cho, Ha Sung Kim, A Reum Choe, Hwi Young Kim, Kwon Yoo, Tae Hun Kim
    Cancers.2021; 13(14): 3424.     CrossRef
  • No Uniformity in the References of Clinical Practice Guidelines for Bariatric Surgery: a Review of 3 Similar Guidelines Published in 2020.
    Mark J. R. Smeets, Ronald S. L. Liem
    Obesity Surgery.2021; 31(12): 5427.     CrossRef
  • Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B
    Hye Won Lee, Young Youn Cho, Hyein Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim, Soo Young Park
    Hepatology International.2021; 15(5): 1083.     CrossRef
  • Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma
    Sojung Han, Hye Jin Choi, Seung-Hoon Beom, Hye Rim Kim, Hyein Lee, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jinsil Seong, Jong Yun Won, Beom Kyung Kim
    Journal of Cancer Research and Clinical Oncology.2021; 147(10): 3123.     CrossRef
  • The Prognostic Role of On-Treatment Liver Stiffness for Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B
    Hye Won Lee, Hyun Woong Lee, Jae Seung Lee, Yun Ho Roh, Hyein Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Journal of Hepatocellular Carcinoma.2021; Volume 8: 467.     CrossRef
  • Critical Updates on Chronic Hepatitis B Virus Infection in 2021
    Cyriac A Philips, Rizwan Ahamed, Jinsha K Abduljaleel, Sasidharan Rajesh, Philip Augustine
    Cureus.2021;[Epub]     CrossRef
  • Revised Korean Antiviral Guideline Reduces the Hepatitis B-related Hepatocellular Carcinoma Risk in Cirrhotic Patients
    David Sooik Kim, Soo Young Park, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Kwang-Hyub Han, Yu Rim Lee, Won Young Tak, Young Oh Kweon, Inkyung Jung, Minkyung Han, Eun Hwa Kim, Sang Hoon Ahn, Seung Up Kim
    Journal of Korean Medical Science.2021;[Epub]     CrossRef
  • Novel Therapies of Hepatitis B and D
    Iman Waheed Khan, Mati Ullah Dad Ullah, Mina Choudhry, Mukarram Jamat Ali, Muhammad Ashar Ali, Sam L. K. Lam, Pir Ahmad Shah, Satinder Pal Kaur, Daryl T. Y. Lau
    Microorganisms.2021; 9(12): 2607.     CrossRef
  • Benefits and Risks of Antiviral Treatment during Pregnancy in Patients with Chronic Hepatitis B
    Yoon Seok Lee, Soo Min Bang, Young-Sun Lee
    Journal of Clinical Medicine.2021; 10(11): 2320.     CrossRef
  • Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B
    Hye Won Lee, Young Youn Cho, Hyein Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim, Soo Young Park
    Journal of Viral Hepatitis.2021; 28(11): 1570.     CrossRef
  • Efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in treatment-naive hepatitis B patients
    Hye Yeon Chon, Sang Hoon Ahn, Yoon Jun Kim, Jung-Hwan Yoon, Jeong-Hoon Lee, Dong Hyun Sinn, Seung Up Kim
    Hepatology International.2021; 15(6): 1328.     CrossRef
  • Progress and challenges in the comprehensive management of chronic viral hepatitis: Key ways to achieve the elimination
    Fátima Higuera-de la Tijera, Alfredo Servín-Caamaño, Luis Servín-Abad
    World Journal of Gastroenterology.2021; 27(26): 4004.     CrossRef
  • Novel Liver Stiffness-Based Nomogram for Predicting Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis B Virus Infection Initiating Antiviral Therapy
    Jae Seung Lee, Hyun Woong Lee, Tae Seop Lim, Hye Jung Shin, Hye Won Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Cancers.2021; 13(23): 5892.     CrossRef
  • 19,319 View
  • 1,478 Download
  • 83 Web of Science
  • Crossref

Original Article

Viral hepatitis

Effect of antiviral therapy in reducing perinatal transmission of hepatitis B virus and maternal outcomes after discontinuing them
Kwang Il Seo, Si Hyun Bae, Pil Soo Sung, Chung-Hwa Park, Hae Lim Lee, Hee Yeon Kim, Hye Ji Kim, Bo Hyun Jang, Jeong Won Jang, Seung Kew Yoon, Jong Young Choi, In-Yang Park, Juyoung Lee, Hyun Seung Lee, Sa-Jin Kim, Jung Hyun Kwon, U Im Chang, Chang Wook Kim, Se Hyun Jo, Young Lee, Fisseha Tekle, Jong-Hyun Kim
Clin Mol Hepatol 2018;24(4):374-383.
Published online June 26, 2018
DOI: https://doi.org/10.3350/cmh.2017.0082
Background/Aims
There have been numerous efforts to reduce mother-to-child transmission (MTCT) of hepatitis B virus (HBV) with antiviral agents during pregnancy. However, there are limited data regarding the outcomes of pregnant women after delivery. This study was performed to evaluate the efficacy of antiviral agents in preventing MTCT of HBV and maternal long-term outcomes.
Methods
The HBV-infected pregnant women treated with antiviral agents to prevent MTCT were retrospectively reviewed. Forty-one pregnant women who received telbivudine or tenofovir during late pregnancy (28-34 week) were analyzed. Hepatitis B virus surface antibody (HBsAb) positivity was tested in 43 infants after 7 months of birth. Eleven mothers were followed >1 year after delivery.
Results
The mean HBV DNA titer before antiviral therapy was 8.67 (6.60–9.49) log copies/mL, and the median age at delivery was 32 years (range, 22–40). Eleven patients were treated with tenofovir and 30 with telbivudine. The median duration was 57 days (range, 23–100), and the median HBV DNA titer at birth was 5.06 log copies/mL (range, 2.06–6.50). Antiviral treatments were associated with significant HBV DNA reduction (P<0.001). Among 43 infants (two cases of twins), HBsAb was not detected in two, subsequently confirmed to have HBV infection. Biochemical flare was observed in two of 11 mothers followed >12 months, and an antiviral agent was administered.
Conclusions
Antiviral treatment during late pregnancy effectively reduced MTCT. Long-term follow-up should be required in such cases. In addition, given that maternal biochemical flare occurred in 18% of mothers, re-administration of antiviral agents might be required.
  • 11,452 View
  • 340 Download
  • 1 Web of Science

Case Report

Viral hepatitis

Favorable effect of corticosteroids in treating acute-on-chronic liver failure underlying chronic hepatitis B
Hyeji Kim, Jung Hyun Kwon, Yong Hee Kim, Soon Woo Nam, Jong Yul Lee, Jeong Won Jang
Clin Mol Hepatol 2018;24(4):430-435.
Published online November 27, 2017
DOI: https://doi.org/10.3350/cmh.2017.0016
Acute-on-chronic liver failure (ACLF) occurs in the presence of a chronic liver disease or cirrhosis, and often results from exacerbation of chronic hepatitis B (CHB). The efficacy of corticosteroid treatment in ACLF patients with underlying CHB remains unclear. We report the case of a 50-year-old woman who experienced ACLF due to CHB exacerbation and was treated with a combination of corticosteroids and nucleot(s)ide analogue (NUC). The patient showed rapid decompensation due to CHB exacerbation. Three months of antiviral therapy produced no improvement in liver function. Combination therapy with corticosteroids and NUC was started, which did result in improvement of liver function. This case shows that the combined therapy of corticosteroids and NUC can be effective in treating ACLF due to CHB exacerbation.

Citations

Citations to this article as recorded by  Crossref logo
  • Metabolic dysfunction-associated steatotic liver disease (MASLD): Exploring systemic impacts and innovative therapies
    Parag Jain, Akanksha Jain, Rohitas Deshmukh, Pradeep Samal, Trilochan Satapathy, Ajazuddin
    Clinics and Research in Hepatology and Gastroenterology.2025; 49(6): 102584.     CrossRef
  • Hypomethylation of thymosin β4 promoter is associated with glucocorticoid therapy in patients with acute-on-chronic hepatitis B-induced liver failure
    He Wang, Yu Qian, Jing-Wen Wang, Yu Fang, Yu-Chen Fan, Hui-Hui Liu, Kai Wang
    International Health.2023; 15(1): 19.     CrossRef
  • Critically Ill COVID-19 Patient with Chronic Liver Disease - Insights into a Comprehensive Liver Intensive Care
    Cyriac Abby Philips, Kamna Kakkar, Moby Joseph, Praveen Kumar Yerol, Rizwan Ahamed, Sasidharan Rajesh, Philip Augustine
    Journal of Clinical and Translational Hepatology.2021; 000(000): 000.     CrossRef
  • 13,010 View
  • 262 Download
  • 3 Web of Science
  • Crossref

Original Article

Hepatic neoplasm

Preemptive antiviral therapy with entecavir can reduce acute deterioration of hepatic function following transarterial chemoembolization
Sun Hong Yoo, Jeong Won Jang, Jung Hyun Kwon, Seung Min Jung, Bohyun Jang, Jong Young Choi
Clin Mol Hepatol 2016;22(4):458-465.
Published online December 25, 2016
DOI: https://doi.org/10.3350/cmh.2016.0054
Background/Aims
Hepatic damage during transarterial chemoembolization (TACE) is a critical complication in patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Apart from its role in preventing HBV reactivation, there is some evidence for the benefits of preemptive antiviral therapy in TACE. This study evaluated the effect of preemptive antiviral therapy on acute hepatic deterioration following TACE.
Methods
This retrospective observational study included a prospectively collected cohort of 108 patients with HBV-related HCC who underwent TACE between January 2007 and January 2013. Acute hepatic deterioration following TACE was evaluated. Treatment-related hepatic decompensation was defined as newly developed encephalopathy, ascites, variceal bleeding, elevation of the bilirubin level, prolongation of prothrombin time, or elevation of the Child-Pugh score by ≥2 within 2 weeks following TACE. Univariate and multivariate analyses were conducted to identify factors influencing treatment-related decompensation. Preemptive antiviral therapy involves directing prophylaxis only toward high-risk chronic hepatitis B patients in an attempt to prevent the progression of liver disease. We regarded at least 6 months as a significant duration of preemptive antiviral treatment before diagnosis of HCC.
Results
Of the 108 patients, 30 (27.8%) patients received preemptive antiviral therapy. Treatment-related decompensation was observed in 25 (23.1%) patients during the follow-up period. Treatment-related decompensation following TACE was observed more frequently in the nonpreemptive group than in the preemptive group (29.5% vs. 6.7%, P=0.008). In the multivariate analysis, higher serum total bilirubin (Hazard ratio [HR] =3.425, P=0.013), hypoalbuminemia (HR=3.990, P=0.015), and absence of antiviral therapy (HR=7.597, P=0.006) were significantly associated with treatment-related hepatic decompensation.
Conclusions
Our findings suggest that preemptive antiviral therapy significantly reduces the risk of acute hepatic deterioration. Preventing hepatic deterioration during TACE by applying such a preemptive approach may facilitate the continuation of anticancer therapy and thus improve long-term outcomes.

Citations

Citations to this article as recorded by  Crossref logo
  • Impact of frailty on the long-term prognosis of the elderly with hepatocellular carcinoma treated with transarterial chemoembolization
    Yu-Fei Shao, Ya-Nan Zu, Xiang-Qi Yin, Jin-Chang Xiao, Yu-Ming Gu
    Scientific Reports.2025;[Epub]     CrossRef
  • EASL Clinical Practice Guidelines on the management of hepatitis B virus infection
    Markus Cornberg, Lisa Sandmann, Jerzy Jaroszewicz, Patrick Kennedy, Pietro Lampertico, Maud Lemoine, Sabela Lens, Barbara Testoni, Grace Lai-Hung Wong, Francesco Paolo Russo
    Journal of Hepatology.2025; 83(2): 502.     CrossRef
  • Microbial metabolism dysfunction induced by transarterial chemoembolization aggravates postprocedural liver injury in HCC
    Rui Li, Jianxin Liu, Feilong Ye, Siqin He, Jingjun Huang, Mengdan Zhou, Qifeng Xie, Zhile Liu, Wei Cheng, Guodong Wang, Wei Deng, Xiaobin Wang, Tingqi Yang, Zhengyang Liang, Feiyan Hu, Wensou Huang, Mingyue Cai, Lulu Xie, Wen Zhang, Shenhai Gong, Yun Chen
    Journal of Hepatology.2025;[Epub]     CrossRef
  • 5-FU promotes HBV replication through oxidative stress-induced autophagy dysfunction
    Jing Yang, Luyan Zheng, Zhenggang Yang, Zhiqiang Wei, Jiajia Shao, Yina Zhang, Jiping Yao, Minwei Li, Xueyu Wang, Min Zheng
    Free Radical Biology and Medicine.2024; 213: 233.     CrossRef
  • Liver Injury and Its Impact on Prognosis in Patients with HBV-Related Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors
    Jiaming Shen, Xia Wang, Guangde Yang, Li Li, Juanjuan Fu, Wei Xu, Qingqiao Zhang, Xiucheng Pan
    Journal of Hepatocellular Carcinoma.2024; Volume 11: 207.     CrossRef
  • Sorafenib plus transcatheter arterial chemoembolization with or without camrelizumab for the treatment of intermediate and advanced hepatocellular carcinoma
    Bo Sun, Lei Chen, Yu Lei, Lijie Zhang, Tao Sun, Yiming Liu, Chuansheng Zheng
    British Journal of Radiology.2024; 97(1159): 1320.     CrossRef
  • TACE versus TACE + entecavir versus TACE + tenofovir in the treatment of HBV associated hepatocellular carcinoma
    Haohao Lu, Chuansheng Zheng, Bin Xiong, Xiangwen Xia
    BMC Cancer.2023;[Epub]     CrossRef
  • S3-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion – (AWMF-Register-Nr. 021-11)
    Markus Cornberg, Lisa Sandmann, Ulrike Protzer, Claus Niederau, Frank Tacke, Thomas Berg, Dieter Glebe, Wolfgang Jilg, Heiner Wedemeyer, Stefan Wirth, Christoph Höner zu Siederdissen, Petra Lynen-Jansen, Pia van Leeuwen, Jörg Petersen
    Zeitschrift für Gastroenterologie.2021; 59(07): 691.     CrossRef
  • Association of Prophylactic Anti–Hepatitis B Virus Therapy With Improved Long-term Survival in Patients With Hepatocellular Carcinoma Undergoing Transarterial Therapy
    Jeong Won Jang, Sun Hong Yoo, Hee Chul Nam, Bo Hyun Jang, Pil Soo Sung, Sung, Won Lee, Jung Hyun Kwon, Soon Woo Nam, Si Hyun Bae, Seung Kew Yoon, Jong Young Choi
    Clinical Infectious Diseases.2020; 71(3): 546.     CrossRef
  • Nucleos(t)ide analogues and Hepatitis B virus-related hepatocellular carcinoma: A literature review
    Mohamed A Abd El Aziz, Rodolfo Sacco, Antonio Facciorusso
    Antiviral Chemistry and Chemotherapy.2020; 28: 204020662092133.     CrossRef
  • Efficacy of microwave ablation and entecavir as a combination treatment for primary liver cancer and their effects on hepatitis B virus and liver function
    Hong Xu, Qiang Zhang, Yu-Lin Tan, Yang Zhang, Jian-Zhu Wei, Ling-Ling Wang, Bo Xie
    All Life.2020; 13(1): 524.     CrossRef
  • Effects of TACE and preventive antiviral therapy on HBV reactivation and subsequent hepatitis in hepatocellular carcinoma: a meta-analysis
    Su-Su Zhang, Jin-Xia Liu, Jing Zhu, Ming-Bing Xiao, Cui-Hua Lu, Run-Zhou Ni, Li-Shuai Qu
    Japanese Journal of Clinical Oncology.2019; 49(7): 646.     CrossRef
  • Hepatitis B virus reactivation after radiotherapy for hepatocellular carcinoma and efficacy of antiviral treatment: A multicenter study
    Baek Gyu Jun, Young Don Kim, Sang Gyune Kim, Young Seok Kim, Soung Won Jeong, Jae Young Jang, Sae Hwan Lee, Hong Soo Kim, Seong Hee Kang, Moon Young Kim, Soon Koo Baik, Minjong Lee, Tae-Suk Kim, Dae Hee Choi, Sang-Hyeon Choi, Ki Tae Suk, Dong Joon Kim, Ga
    PLOS ONE.2018; 13(7): e0201316.     CrossRef
  • 11,758 View
  • 138 Download
  • 12 Web of Science
  • Crossref

Case Report

Steatotic liver disease

Severe steatohepatitis with hepatic decompensation resulting from malnutrition after pancreaticoduodenectomy
Eun Hui Sim, Jung Hyun Kwon, Se Young Kim, Seung Min Jung, Lee-So Maeng, Jeong Won Jang, Kyu Won Chung
Korean J Hepatol 2012;18(4):404-410.
Published online December 21, 2012
DOI: https://doi.org/10.3350/cmh.2012.18.4.404

The most common finding related to nonalcoholic steatohepatitis is obesity, but a status of severe malnutrition can also induce the steatohepatitis. The authors report a rare case of steatohepatitis leading to hepatic decompensation caused by malnutrition after pancreaticoduodenectomy. A 68-year-old female patient who had been previously diagnosed with pancreatic cancer and had undergone pancreaticoduodenectomy 5 months previously presented with abdominal distension. Routine CT performed 3 months after the surgery revealed severe fatty liver without evidence of tumor recurrence. After undergoing pancreaticoduodenectomy her food intake had reduced, and as a result she had lost 7 kg of body weight over 2 months. At this admission, CT revealed moderate amounts of ascites without tumor recurrence. Furthermore, her albumin and lipid profile levels were markedly decreased, and she had a flapping tremor and slurred speech suggestive of hepatic encephalopathy. Her liver biopsy findings were consistent with steatohepatitis and disclosed macrovesicular steatosis without definite fibrosis. After careful nutritional control, her symptoms disappeared and her laboratory findings improved.

Citations

Citations to this article as recorded by  Crossref logo
  • Cirrhosis after pancreaticoduodenectomy for pancreatic cancer
    Rui Su, Hong-Na Liu, Yu-Bo Wang, Yun Bai
    Hepatobiliary & Pancreatic Diseases International.2025; 24(2): 232.     CrossRef
  • Liver Transplantation for Metabolic Dysfunction-Associated Steatotic Liver Disease after Pancreaticoduodenectomy
    Takeshi Kano, Ryugen Takahashi, Nobuhisa Akamatsu, Yujiro Nishioka, Yuichiro Mihara, Akihiko Ichida, Takeshi Takamoto, Yoshikuni Kawaguchi, Kiyoshi Hasegawa
    Surgical Case Reports.2025; 11(1): n/a.     CrossRef
  • Are transmembrane 6 superfamily member 2 gene polymorphisms associated with steatohepatitis after pancreaticoduodenectomy?
    Tomotaka Mori, Eisuke Ozawa, Ryu Sasaki, Akane Shimakura, Kosuke Takahashi, Yoko Kido, Yasuko Kanda, Satoshi Matsuo, Kazuaki Tajima, Asami Beppu, Yasuhiko Nakao, Masanori Fukushima, Masafumi Haraguchi, Satoshi Miuma, Hisamitsu Miyaaki, Tomohiko Adachi, Su
    JGH Open.2024;[Epub]     CrossRef
  • Review article: Hepatic steatosis and its associations with acute and chronic liver diseases
    Aaron B. Koenig, Albert Tan, Hala Abdelaal, Fanny Monge, Zobair M. Younossi, Zachary D. Goodman
    Alimentary Pharmacology & Therapeutics.2024; 60(2): 167.     CrossRef
  • Prevalence of metabolic dysfunction-associated fatty liver disease after pancreatic surgery in a historical Belgian cohort and review of the literature
    V D’Cruz, A De Zutter, M Van den Broecke, S Ribeiro, L Abreu de Carvalho, P Smeets, C Lecluyse, E Pape, E Callebout, F Berrevoet, K Geboes
    Acta Gastro Enterologica Belgica.2024; 87(3): 373.     CrossRef
  • Hepatic Steatosis After Partial Pancreatectomy in a Cohort of Patients with Intraductal Papillary Mucinous Neoplasm
    Zhenteng Li, Jonathan Weinstein, Ellen Redstone, Donald G. Mitchell
    Journal of Clinical and Experimental Hepatology.2023; 13(6): 955.     CrossRef
  • Association Between Neoadjuvant Chemoradiotherapy and Intractable Serous Ascites After Pancreaticoduodenectomy for Pancreatic Cancer
    Atsushi Tomioka, Tetsunosuke Shimizu, Shuji Kagota, Kohei Taniguchi, Koji Komeda, Mitsuhiro Asakuma, Fumitoshi Hirokawa, Kazuhisa Uchiyama
    Annals of Surgical Oncology.2021; 28(7): 3789.     CrossRef
  • Nonalcoholic Fatty Liver Disease After Pancreaticoduodenectomy for a Cancer Diagnosis
    Amy E. McGhee-Jez, Inna Chervoneva, Misung Yi, Amisha Ahuja, Ritu Nahar, Samik Shah, Rebecca Loh, Sarah Houtmann, Rashesh Shah, Charles J. Yeo, Harish Lavu, Steven J. Cohen, Dina Halegoua-DeMarzio, Atrayee Basu Mallick
    Journal of Pancreatic Cancer.2021; 7(1): 23.     CrossRef
  • Preventive Effect of High-Dose Digestive Enzyme Management on Development of Nonalcoholic Fatty Liver Disease after Pancreaticoduodenectomy: A Randomized Controlled Clinical Trial
    Koya Yasukawa, Akira Shimizu, Takahide Yokoyama, Koji Kubota, Tsuyoshi Notake, Hitoshi Seki, Akira Kobayashi, Yuji Soejima
    Journal of the American College of Surgeons.2020; 231(6): 658.     CrossRef
  • New onset non‐alcoholic fatty liver disease after resection of pancreatic neuroendocrine tumors
    Tara Michella Mackay, Cansu Güney Genç, Robert Bart Takkenberg, Marc Gerard Besselink, Inne Somers, Elisabeth Jacqueline Maria Nieveen van Dijkum
    Journal of Surgical Oncology.2018; 117(7): 1548.     CrossRef
  • Risk Factors for and Management of Postpancreatectomy Hepatic Steatosis
    N. Takemura, A. Saiura, R. Koga, J. Yamamoto, T. Yamaguchi
    Scandinavian Journal of Surgery.2017; 106(3): 224.     CrossRef
  • Risk factors for development of nonalcoholic fatty liver disease after pancreatoduodenectomy
    Yoshiro Fujii, Atsushi Nanashima, Masahide Hiyoshi, Naoya Imamura, Koichi Yano, Takeomi Hamada
    Annals of Gastroenterological Surgery.2017; 1(3): 226.     CrossRef
  • Clinical Characteristics and Risk Factors for the Development of Postoperative Hepatic Steatosis After Total Pancreatectomy
    Tatsuo Hata, Masaharu Ishida, Fuyuhiko Motoi, Naoaki Sakata, Gumpei Yoshimatsu, Takeshi Naitoh, Yu Katayose, Shinichi Egawa, Michiaki Unno
    Pancreas.2016; 45(3): 362.     CrossRef
  • Pathophysiology after pancreaticoduodenectomy
    Chang Moo Kang, Jin Ho Lee
    World Journal of Gastroenterology.2015; 21(19): 5794.     CrossRef
  • Nonalcoholic fatty liver disease after pancreatoduodenectomy is closely associated with postoperative pancreatic exocrine insufficiency
    Naoya Nakagawa, Yoshiaki Murakami, Kenichiro Uemura, Takeshi Sudo, Yasushi Hashimoto, Naru Kondo, Hayato Sasaki, Keisuke Okano, Taijiro Sueda
    Journal of Surgical Oncology.2014; 110(6): 720.     CrossRef
  • Prevalence Analysis of de novo Hepatic Steatosis Following Pylorus-Preserving Pancreaticoduodenectomy
    Dae-Gwang Yoo, Bo-Hyun Jung, Shin Hwang, Song-Chul Kim, Ki-Hun Kim, Young-Joo Lee, Chul-Soo Ahn, Deok-Bog Moon, Kang-Mo Kim, Tae-Yong Ha, Sung-Hwa Kang, Nayoung Kim
    Digestive Surgery.2014; 31(4-5): 359.     CrossRef
  • Liver disease and malnutrition
    Tugrul Purnak, Yusuf Yilmaz
    Best Practice & Research Clinical Gastroenterology.2013; 27(4): 619.     CrossRef
  • A rapidly progressive and fatal case of nonalcoholic steatohepatitis following pancreaticoduodenectomy
    Hideaki Miura, Masayoshi Ijichi, Yoshitaka Ando, Korenobu Hayama, Kuniko IIhara, Haruki Yamada, Yasutsugu Bandai
    Clinical Journal of Gastroenterology.2013; 6(6): 470.     CrossRef
  • 10,044 View
  • 89 Download
  • Crossref
Original Article
Differences in the patterns and outcomes of enhanced viral replication between hepatitis C virus and hepatitis B virus in patients with hepatocellular carcinoma during transarterial chemolipiodolization
Pil Soo Sung, Si Hyun Bae, Jeong Won Jang, Do Seon Song, Hee Yeon Kim, Sun Hong Yoo, Chung-Hwa Park, Jung Hyun Kwon, Myeong Jun Song, Chan Ran You, Jong Young Choi, Seung Kew Yoon
Korean J Hepatol 2011;17(4):299-306.
Published online December 26, 2011
DOI: https://doi.org/10.3350/kjhep.2011.17.4.299
Background/Aims

Enhanced replication of hepatitis C virus (HCV) is well described in the setting of moderate to severe immunosuppression. The aims of this retrospective study were to determine the incidence of enhanced HCV replication in hepatocellular carcinoma (HCC) patients undergoing transarterial chemolipiodolization (TACL) and to identify the factors associated with enhanced replication of HCV. The clinical pattern of enhanced HCV replication was compared with hepatitis B virus (HBV) reactivation during TACL.

Methods

This study enrolled 49 anti-HCV-seropositive patients who were diagnosed with HCC between January 2005 and December 2010 and who underwent TACL using epirubicin and/or cisplatin with consecutive HCV RNA copies checked. For comparison, 46 hepatitis B surface antigen1-positive patients with HCC who were treated with TACL were also enrolled. The frequency, associated factors, and clinical outcomes of enhanced HCV replication were analyzed and compared with those of HBV reactivation during TACL.

Results

Enhanced replication of HCV occurred in 13 (26.5%) of the 49 anti-HCV-seropositive patients during TACL. Of these 13 patients, 4 developed hepatitis, but none of the subjects developed decompensation due to the hepatitis. No significant clinical factors for enhanced HCV replication during TACL were found. Compared with HBV reactivation, the frequency of hepatitis attributed to enhanced HCV replication was significantly lower than that for HBV reactivation (8.2% vs. 23.9%, P=0.036).

Conclusions

TACL can enhance HCV replication; however, the likelihood of hepatitis and decompensation stemming from enhanced HCV replication was lower than that for HBV reactivation in patients undergoing TACL.

Citations

Citations to this article as recorded by  Crossref logo
  • 5-FU promotes HBV replication through oxidative stress-induced autophagy dysfunction
    Jing Yang, Luyan Zheng, Zhenggang Yang, Zhiqiang Wei, Jiajia Shao, Yina Zhang, Jiping Yao, Minwei Li, Xueyu Wang, Min Zheng
    Free Radical Biology and Medicine.2024; 213: 233.     CrossRef
  • 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

    Journal of Liver Cancer.2023; 23(1): 1.     CrossRef
  • 2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma

    Korean Journal of Radiology.2022; 23(12): 1126.     CrossRef
  • 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

    Clinical and Molecular Hepatology.2022; 28(4): 583.     CrossRef
  • AISF position paper on HCV in immunocompromised patients
    Alfredo Marzano, Emanuele Angelucci, Marco Astegiano, Chiara Baratelli, Luigi Biancone, Paolo Bironzo, Giuseppina Brancaccio, Maurizia Rossana Brunetto, Raffaele Bruno, Patrizia Burra, Maria Giuseppina Cabras, Paolo Caraceni, Claudia Chialà, Maria Grazia
    Digestive and Liver Disease.2019; 51(1): 10.     CrossRef
  • 2018 Korean Liver Cancer Association–National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma
    KLCA Korean Liver Cancer Association, NCC National Cancer Center
    Gut and Liver.2019; 13(3): 227.     CrossRef
  • 2018 Korean Liver Cancer Association–National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma

    Korean Journal of Radiology.2019; 20(7): 1042.     CrossRef
  • Reactivation of Hepatitis C Virus and Its Clinical Outcomes in Patients Treated with Systemic Chemotherapy or Immunosuppressive Therapy
    Hae Lim Lee, Si Hyun Bae, Bohyun Jang, Seawon Hwang, Hyun Yang, Hee Chul Nam, Pil Soo Sung, Sung Won Lee, Jeong Won Jang, Jong Young Choi, Nam Ik Han, Byung Joo Song, Jong Wook Lee, Seung Kew Yoon
    Gut and Liver.2017; 11(6): 870.     CrossRef
  • 2014 Korean Liver Cancer Study Group-National Cancer Center Korea Practice Guideline for the Management of Hepatocellular Carcinoma

    Korean Journal of Radiology.2015; 16(3): 465.     CrossRef
  • Management of viral hepatitis in patients with hepatocellular carcinoma
    Jeong Won Jang
    Journal of the Korean Medical Association.2013; 56(11): 1001.     CrossRef
  • 8,420 View
  • 50 Download
  • Crossref